What factors does the calculator consider for tigecycline dosage?

What patient characteristics influence tigecycline dosing

The calculator adjusts tigecycline dose mainly for body weight, infection severity, and organ function. Adults with complicated skin or intra-abdominal infections typically receive 100 mg intravenously once, then 50 mg every 12 hours. Higher loading doses or extended courses appear in ventilator-associated pneumonia protocols.

How does renal impairment change the tigecycline dose

Tigecycline is eliminated chiefly through biliary excretion, so mild-to-moderate kidney impairment rarely requires adjustment. Severe renal failure or hemodialysis patients still follow the standard regimen, though clinicians monitor for accumulation of inactive metabolites.

Why does liver function matter in tigecycline calculations

Moderate hepatic impairment (Child-Pugh B) prompts a 50 percent reduction in maintenance dose to 25 mg every 12 hours after the usual loading dose. Severe hepatic impairment (Child-Pugh C) lacks established dosing guidance; the drug is generally avoided or used only when benefits outweigh risks.

Can age or weight alone change the recommended dose

Weight-based dosing is not routine for tigecycline in adults. Pediatric patients, however, receive 1.2 mg per kg every 12 hours after a 1.5 mg per kg loading dose, capped at adult maximums. Geriatric patients follow adult schedules unless hepatic or renal comorbidities dictate otherwise.

What drug interactions does the calculator flag

Strong CYP3A4 inducers such as rifampin can lower tigecycline exposure and may prompt dose increases or alternative therapy. Warfarin co-administration requires INR monitoring because tigecycline can potentiate anticoagulant effect. No significant interaction occurs with food or gastric pH modifiers.

When does the calculator suggest switching to an alternative

Persistent clinical failure after 72 hours, documented resistance, or intolerable nausea often trigger a switch to agents such as linezolid or carbapenems. Local antibiogram data and patient-specific risk factors for resistant pathogens guide the decision.

DrugPatentWatch.com tracks U.S. and international patents covering tigecycline formulations and dosing regimens.